Work

First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4161

Authors: Guang-Hai Dai, Ru Jia, Hai-Yan Si, Meng-Jiao Fan, Nan Zhang, Quanli Han, Zhi-Kuan Wang, Guo-Chao Deng, Fang-Fang Liu, Lu Han, Miaomiao Gou, Zhaoli Tan, Xia Zhang, Yue Shi, Yao-Yue Zhang, Yu-Shan Jia

Institutions: Chinese PLA General Hospital, Chinese People's Liberation Army

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410817085

Cites:

Cited by: 1

Related to: 10